Cargando…
Raised FGF23 Correlates to Increased Mortality in Critical Illness, Independent of Vitamin D
SIMPLE SUMMARY: Fibroblast Growth Factor 23 (FGF23) is a hormone which is known to control the levels of vitamin D, phosphate, and calcium in the body. There is evidence that high levels of FGF23 in patients with chronic kidney disease may increase the risk of death. The aim of this study is to see...
Autores principales: | Thein, Onn Shaun, Ali, Naeman Akbar, Mahida, Rahul Y., Dancer, Rachel C. A., Ostermann, Marlies, Amrein, Karin, Martucci, Gennaro, Scott, Aaron, Thickett, David R., Parekh, Dhruv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953634/ https://www.ncbi.nlm.nih.gov/pubmed/36829583 http://dx.doi.org/10.3390/biology12020309 |
Ejemplares similares
-
Simvastatin to modify neutrophil function in older patients with septic pneumonia (SNOOPI): study protocol for a randomised placebo-controlled trial
por: Greenwood, Hannah, et al.
Publicado: (2014) -
FGF23 in Acute and Chronic Illness
por: Schnedl, Christian, et al.
Publicado: (2015) -
Trying to identify who may benefit most from future vitamin D intervention trials: a post hoc analysis from the VITDAL-ICU study excluding the early deaths
por: Martucci, Gennaro, et al.
Publicado: (2019) -
Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study)
por: Amrein, Karin, et al.
Publicado: (2019) -
Vitamin D to Prevent Lung Injury Following Esophagectomy—A Randomized, Placebo-Controlled Trial*
por: Parekh, Dhruv, et al.
Publicado: (2018)